相关实验视频

Updated: Jul 3, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.4K

发现了新型TLR7激动剂作为与aPD1结合使用的系统性剂,用于免疫瘤学

Yam B Poudel1, Liqi He1, Matthew Cox1

  • 1Bristol-Myers Squibb Research & Development, 700 Bay Road, Redwood City, California 94063, United States.

ACS medicinal chemistry letters
|February 14, 2024
PubMed
概括

新型托尔类受体7 (TLR7) 激动剂表现出强烈的活性,在与aPD1疗法结合时诱导细胞因子分泌和协同作用的抗瘤作用. 这些发现突出了潜在的新癌症治疗策略.

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

316
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524